Flamel Technologies develops and markets pharmaceutical products that address unmet medical needs and reduce healthcare costs. They currently sell three previously unapproved drugs in the US and have proprietary drug delivery platforms for sustained release and abuse-resistant opioids. They also have a long-acting injectable platform and are working on developing formulations for various drugs. Flamel Technologies is listed on NASDAQ and is dedicated to improving drug formulations to meet medical needs.